Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Robin, Alan L., M.D.
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently using one or two topical ocular hypotensive medications